Research Reports

Key takeaways

The company raised approximately $10.0 million in a private placement by selling 7,827,789 units to funds affiliated with BVF Partners LP, with each unit priced at $1.2775.

The private placement closed on April 2, 2026, with the company agreeing to file a registration statement within 30 days to register the resale of the shares and shares issuable upon warrant exercise.

Net proceeds from the offering are intended to support the initiation of a phase 3 registrational study of EB613 in postmenopausal women with osteoporosis and for general working capital and corporate purposes.

The securities were offered in reliance on an exemption from registration under Section 4(a)(2) of the Securities Act, with the purchaser representing it is an accredited investor.

If all Ordinary Share Warrants were exercised for cash, the company would expect to receive additional proceeds of approximately $14.5 million.

Full analysis

Entera Bio Ltd. has secured approximately $10.0 million in financing through a private placement to a single institutional investor, funds affiliated with BVF Partners LP. The transaction structure involves the sale of units, each consisting of one ordinary share (or in lieu thereof, one pre-funded warrant) and one warrant to purchase one and a half ordinary shares. The financing provides immediate capital to advance the company's lead clinical program, EB613 for osteoporosis, into a phase 3 registrational study, which represents a critical development milestone. The company has committed to registering the resale of the securities, providing the investor with potential liquidity. The warrants contain exercise price protections and ownership limitations, with the ordinary share warrants carrying a five-year term and becoming exercisable six months after closing. This financing reduces near-term funding risk for the company's clinical development plans.

ENTX · Entera Bio Ltd.

Summary

Key takeaways

Full analysis